 The China National Medical Products Administration NMPA has conditionally approved Kyprolis carfilzomib for relapsed or refractory RR multiple myeloma. The approval covers Kyprolis in combination with dexamethasone for adult patients who have received at least two prior therapies, including a proteasome inhibitor and an immunomodulatory agent. 